March 5, 2021
Business News

bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress

CAMBRIDGE, Mass.–()–bluebird bio, Inc. (NASDAQ:BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and shared recent operational progress.

“For over ten years, bluebird bio has been pioneering gene therapies for patients with rare diseases and cancer, and our work continues with the analysis of the recent safety events identified in our HGB-206 study in patients with sickle cell disease. We have seen the transformative benefit of these therapies and are conducting a scientific and medical investigation to best inform our path forward on behalf of the patients we hope to serve with LentiGlobin,” said Nick Leschly, chief bluebird. “While…

Click here to view the original article.

Related Posts

You might also like ...

Moody’s Analytics Wins IFRS 9 Solution Provider of the Year
AON Splash Image
ClosingCorp Names Christine Boring as Chief Product Officer
OSI Systems Receives $15 Million for Airport Security Inspection Systems